Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Inspire Medical Systems (INSP) EBITDA (2017 - 2026)

Inspire Medical Systems' EBITDA history spans 10 years, with the latest figure at -$1.1 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 141.67% to -$1.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $141.5 million, a 112.51% increase, with the full-year FY2025 number at $145.4 million, up 172.98% from a year prior.
  • EBITDA hit -$1.1 million in Q1 2026 for Inspire Medical Systems, down from $135.9 million in the prior quarter.
  • Over the last five years, EBITDA for INSP hit a ceiling of $135.9 million in Q4 2025 and a floor of -$17.0 million in Q3 2022.
  • Historically, EBITDA has averaged $7.8 million across 5 years, with a median of -$1.1 million in 2026.
  • Biggest five-year swings in EBITDA: soared 352.85% in 2023 and later tumbled 141.67% in 2026.
  • Tracing INSP's EBITDA over 5 years: stood at $3.4 million in 2022, then skyrocketed by 352.85% to $15.5 million in 2023, then soared by 119.47% to $34.1 million in 2024, then surged by 299.05% to $135.9 million in 2025, then tumbled by 100.82% to -$1.1 million in 2026.
  • Business Quant data shows EBITDA for INSP at -$1.1 million in Q1 2026, $135.9 million in Q4 2025, and $10.2 million in Q3 2025.